专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20150164797A1 RICE BRAN-LIPIDS BASED FORMULATION AND PROCESS FOR PREPARATION THEREOF FOR SELECTIVE DELIVERY OF GENES TO CANCER CELLS 有权
标题翻译：基于大豆品系的制剂及其制备方法，用于选择性递送基因到癌细胞
公开(公告)号：US20150164797A1
公开(公告)日：2015-06-18
申请号：US14406895
申请日：2013-06-11
申请人： Council Of Scientific And Industrial Research
发明人： Sayantani Roy , Rajkumar Banerjee , Pradosh Prasad Chakrabarti , Badari Narayana, Prasad Rachapudi
IPC分类号： A61K9/127 , A61K38/17 , A61K38/18 , A61K38/45 , A61K38/50 , A61K47/44 , A61K38/19
CPC分类号： A61K9/127 , A61K9/1272 , A61K9/1277 , A61K38/1758 , A61K38/1841 , A61K38/191 , A61K38/45 , A61K38/50 , A61K47/24 , A61K47/44 , A61K48/00
摘要： The present invention relates to a formulation in which glycolipids and phospholipids, isolated from rice bran gum samples, were used in conjunction with gene carrying lipids to test its efficacy in delivering genes to cancer cells selectively. This formulation did not mediate efficient delivery of genes to non-cancerous cells, thus, showing potential use of this formulation to deliver anticancer therapeutics to cancer cells without eliciting treatment related toxicity to normal cells
摘要翻译：本发明涉及一种制剂，其中将从米糠胶样品中分离出的糖脂和磷脂与携带脂质的基因结合使用以测试其在选择性地向癌细胞递送基因的功效。该制剂没有介导基因到非癌细胞的有效递送，因此，显示出该制剂潜在的用途，将抗癌治疗剂递送至癌细胞，而不引起治疗与正常细胞相关的毒性

2. 发明授权

US09763881B2 Rice bran-lipids based formulation and process for preparation thereof for selective delivery of genes to cancer cells 有权
公开(公告)号：US09763881B2
公开(公告)日：2017-09-19
申请号：US14406895
申请日：2013-06-11
申请人： Council Of Scientific And Industrial Research
发明人： Sayantani Roy , Rajkumar Banerjee , Pradosh Prasad Chakrabarti , Badari Narayana Prasad Rachapudi
IPC分类号： A61K9/127 , A61K38/17 , A61K38/18 , A61K38/19 , A61K38/45 , A61K38/50 , A61K47/44 , A61K47/24 , A61K48/00
CPC分类号： A61K9/127 , A61K9/1272 , A61K9/1277 , A61K38/1758 , A61K38/1841 , A61K38/191 , A61K38/45 , A61K38/50 , A61K47/24 , A61K47/44 , A61K48/00
摘要： The present invention relates to a formulation in which glycolipids and phospholipids, isolated from rice bran gum samples, were used in conjunction with gene carrying lipids to test its efficacy in delivering genes to cancer cells selectively. This formulation did not mediate efficient delivery of genes to non-cancerous cells, thus, showing potential use of this formulation to deliver anticancer therapeutics to cancer cells without eliciting treatment related toxicity to normal cells.

3. 发明授权

US09861653B2 Synergistic anti-cancer composition and a process for the preparation thereof 有权
公开(公告)号：US09861653B2
公开(公告)日：2018-01-09
申请号：US14427814
申请日：2013-09-12
申请人： Council of Scientific and Industrial Research , Mayo Foundation for Medical Education and Research
发明人： Rajkumar Banerjee , Debabrata Mukhopadhyay
IPC分类号： A61K9/127 , A61K31/496 , A61K31/4439 , A61K31/575 , A61K48/00 , B82Y5/00 , A61K31/7105 , A61K31/573 , A61K31/567 , A61K45/06 , A61K9/00 , C12N15/113
CPC分类号： A61K31/7105 , A61K9/0019 , A61K9/127 , A61K31/496 , A61K31/567 , A61K31/573 , A61K31/575 , A61K45/06 , C12N15/1138 , C12N2310/14 , C12N2310/531 , A61K2300/00
摘要： The present invention provides an anti-cancer lipid-based composition that kills very aggressive pancreatic cancer cells and breast cancer stem cell (CSC)-like cells. This composition is a concoction of an anti-cancer agent, ESC8 and a glucocorticoid receptor (GR)-targeting cationic lipid delivery system, DX which is further complexed with plasmid DNA. This composition shows anti-cancer effect and initiates killing of cancer cells and CSC-like cells within 3 h. When anti-cancer gene encoded plasmid is used, residual cancer cells were also significantly eradicated after 2 days of exposure. The formulation-free naked ESC8 requires at least ten-fold more concentration and 3 days of continuous treatment to get a similar level of killing. The composition could also inhibit the tumor growth in mice orthotopically implanted with very aggressive mouse breast cancer cell, ANV-1. This cell is known to produce breast CSC-like cells that show phenotype of advanced cancer relapsing. There is no visible toxic effect of this composition when injected in mice, indicating that it has minimum to no toxic effect to normal homeostasis. The present invention is likely to find specific application in developing potential therapeutic treatment for aggressive cancers and CSC-like cancers.

4. 发明申请

US20150283166A1 SYNERGISTIC ANTI-CANCER COMPOSITION AND A PROCESS FOR THE PREPARATION THEREOF 有权
标题翻译：协同抗癌组合物及其制备方法
公开(公告)号：US20150283166A1
公开(公告)日：2015-10-08
申请号：US14427814
申请日：2013-09-12
申请人： COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH , MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
发明人： Rajkumar Banerjee , Debabrata Mukhopadhyay
IPC分类号： A61K31/7105 , A61K31/573 , C12N15/113 , A61K31/496 , A61K45/06 , A61K9/00 , A61K9/127 , A61K31/567
CPC分类号： A61K31/7105 , A61K9/0019 , A61K9/127 , A61K31/496 , A61K31/567 , A61K31/573 , A61K31/575 , A61K45/06 , C12N15/1138 , C12N2310/14 , C12N2310/531 , A61K2300/00
摘要： The present invention provides an anti-cancer lipid-based composition that kills very aggressive pancreatic cancer cells and breast cancer stem cell (CSC)-like cells. This composition is a concoction of an anti-cancer agent, ESC8 and a glucocorticoid receptor (GR)-targeting cationic lipid delivery system, DX which is further complexed with plasmid DNA. This composition shows anti-cancer effect and initiates killing of cancer cells and CSC-like cells within 3 h. When anti-cancer gene encoded plasmid is used, residual cancer cells were also significantly eradicated after 2 days of exposure. The formulation-free naked ESC8 requires at least ten-fold more concentration and 3 days of continuous treatment to get a similar level of killing. The composition could also inhibit the tumor growth in mice orthotopically implanted with very aggressive mouse breast cancer cell, ANV-1. This cell is known to produce breast CSC-like cells that show phenotype of advanced cancer relapsing. There is no visible toxic effect of this composition when injected in mice, indicating that it has minimum to no toxic effect to normal homeostasis. The present invention is likely to find specific application in developing potential therapeutic treatment for aggressive cancers and CSC-like cancers.
摘要翻译：本发明提供一种抗癌脂质组合物，其杀死非常侵袭性的胰腺癌细胞和乳腺癌干细胞（CSC）样细胞。该组合物是抗癌剂，ESC8和糖皮质激素受体（GR） - 靶向阳离子脂质递送系统DX，其与质粒DNA进一步复合。该组合物在3小时内显示出抗癌作用并引发癌细胞和CSC样细胞的杀伤。当使用抗癌基因编码质粒时，暴露2天后，残留的癌细胞也被大量根除。无配方的裸ESC8需要至少十倍的浓度和3天的连续治疗以获得类似的杀死水平。该组合物还可以抑制小鼠原位移植非常侵袭性的小鼠乳腺癌细胞ANV-1的肿瘤生长。已知该细胞产生显示晚期癌症复发表型的乳腺CSC样细胞。当注射到小鼠中时，该组合物没有明显的毒性作用，表明它对正常体内平衡具有最小的无毒性作用。本发明可能在开发针对侵袭性癌症和CSC样癌症的潜在治疗性治疗中发现具体应用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式